Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 06 Oct 2025
Amgen makes Repatha available though AmgenNow, a direct to patient program in the US
6 October 2025 - Eligible patients can access Repatha at nearly 60% discount from the list price. ...
Posted by Michael Wonder on 05 Oct 2025
Why Pfizer’s Trump deal is good news for all of big pharma
2 October 2025 - The company’s accord with the president clears a cloud over the whole sector. ...
Posted by Michael Wonder on 04 Oct 2025
Alzinova receives fast track designation from US FDA for ALZ-101 in Alzheimer’s disease
4 October 2025 - Alzinova today announces that the US FDA has granted fast track designation for the company’s vaccine candidate ...
Posted by Michael Wonder on 04 Oct 2025
Andexanet alfa for haemorrhage: hope not fulfilled
1 October 2025 - A comparative study conducted at the instigation of the EMA shows only negative effects. ...
Posted by Michael Wonder on 04 Oct 2025
Engaging stakeholders along health technology assessment pathways: a scoping review of international practice
30 September 2025 - Health technology assessment has been characterised as a complex adaptive system that centrally features stakeholder interactions. ...
Posted by Michael Wonder on 04 Oct 2025
Ensem Therapeutics announces ETX-636 granted fast track designation by the FDA for advanced breast cancer
1 October 2025 - Ensem Therapeutics today announced the US FDA granted fast track designation to its clinical stage pan mutant-specific ...
Posted by Michael Wonder on 04 Oct 2025
Does big pharma gouge Americans?
2 October 2025 - In the bloated health care system, others are the real money makers. ...
Posted by Michael Wonder on 04 Oct 2025
FDA approves Roche’s Tecentriq plus lurbinectedin as first-line maintenance therapy for extensive-stage small cell lung cancer
3 October 2025 - Regimen recommended in National Comprehensive Cancer Network Guidelines for small cell lung cancer. ...
Posted by Michael Wonder on 03 Oct 2025
Alto Neuroscience receives FDA fast track designation for ALTO-101 for the treatment of cognitive impairment associated with schizophrenia
3 October 2025 - Alto Neuroscience today announced that the US FDA has granted fast track designation to ALTO-101 for the ...
Posted by Michael Wonder on 03 Oct 2025
Bristol Myers Squibb plans to launch Cobenfy (xanomeline and trospium chloride) in the UK at a list price equal to the US launch price
22 September 2025 - Bristol Myers Squibb plans to launch Cobenfy (xanomeline and trospium chloride), in the UK in 2026. ...
Posted by Michael Wonder on 03 Oct 2025
Health Canada approves Agamree (vamorolone) as the first treatment for Duchenne muscular dystrophy in Canada
2 October 2025 - Kye Pharmaceuticals announced today that Health Canada has approved Agamree (vamorolone) for the treatment of Duchenne muscular ...
Posted by Michael Wonder on 03 Oct 2025
Nacuity Pharmaceuticals granted US FDA breakthrough therapy designation for NPI-001 (N-acetylcysteine amide) tablets for the treatment of retinitis pigmentosa
2 October 2025 - Nacuity Pharmaceuticals today announced that the US FDA has granted breakthrough therapy designation to NPI-001 (N-acetylcysteine amide) ...
Posted by Michael Wonder on 03 Oct 2025
FDA approves lurbinectedin in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs for extensive-stage small cell lung cancer
2 October 2025 - Today, the FDA approved lurbinectedin (Zepzelca, Jazz Pharmaceuticals) in combination with atezolizumab (Tecentriq) or atezolizumab and ...
Posted by Michael Wonder on 03 Oct 2025
Taysha Gene Therapies announces FDA breakthrough therapy designation and provides positive regulatory update on TSHA-102 in Rett syndrome
2 October 2025 - Breakthrough therapy designation granted based on FDA’s review of available clinical evidence of safety and efficacy from ...
Posted by Michael Wonder on 02 Oct 2025
Calico Life Sciences announces US FDA fast track designation for investigational treatment of autosomal dominant polycystic kidney disease
2 October 2025 - Calico Life Sciences today announced the US FDA granted fast track designation for ABBV-CLS-628, an investigational therapy ...